Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC
Clinical trial NCT04811027 · COMPLETED
Trial details
- NCT number
- NCT04811027
- Sponsor
- Immutep S.A.S.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-27
- Primary completion
- 2024-03-11
- Enrollment
- 171
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.